Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Roche Diagnostics Sees Data Sourcing, AI and Partnerships As Paving The Way to Personalized Health Care, But Challenges Remain
Two Roche Diagnostics executives outlined the company's vision toward personalized health care. Machine learning, partnerships and data sourcing are key.
Latest From Companies
Execs On The Move: Operating And Science Appointments At Accelerate And BioTelemetry; Leadership Change At Revenio
In vitro testing company Accelerate Diagnostics fills COO slot; remote medical technology firm BioTelemetry appoints a CMO; a new chief executive is in place at medical measuring instruments-maker Revenio Group; and more.
Boston Scientific has completed the acquisition of UK interventional medicine specialist BTG. The deal, which was announced in November last year is Boston Scientific’s biggest since its controversial 2006 acquisition of heart device maker Guidant Corp. for $27bn.
AtriCure Inc. has closed a $300m structured deal to acquire SentreHEART Inc., the privately held developer of the Lariat percutaneous left atrial appendage (LAA) closure device. See what AtriCure CEO Michael Carrel said about it here.
AtriCure Inc. has closed a $300m structured deal to acquire SentreHEART Inc., a privately held developer of percutaneous left atrial appendage management solutions.
Siemens Healthineers AG has signed a billion-dollar deal to merge with US firm Corindus Vascular Robotics, expanding the German company's advanced therapies business.
Neuromodulation firm Nexstim has received regulatory clearance for its SmartFocus TMS system for treating major depressive disorder (MDD) in Australia.
US regulators have notified the public about a recall of certain Abbott Ellipse implantable cardioverter defibrillators that are prone to electrical shorting due a manufacturing flaw. While the number of devices so far in the US is very small, the recall highlights continued issues with the ICDs since Abbott acquired them from St. Jude almost three years ago.
Zimmer Biomet says its long-term plan to return to steady growth is ahead of schedule. See what company CEO Bryan Hanson said about it here.
Zimmer Biomet’s net sales were up 1.2% year-over-year in the second quarter. CEO Bryan Hanson said the ROSA Knee robotic surgery system is performing even better than expected since it launched earlier this year, and is expected to be an important revenue-driver in the future.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.